Beijing Pearl Biotechnology Limited Liability Company
8 clinical trials · Sponsor
◉ Watch Beijing Pearl Biotechnology Limited Liability Company
| Record | Firm | Date |
|---|---|---|
| A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive (NCT06930794) | Beijing Pearl Biotechnology Limited Liability Company | 2025-07-07 |
| A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (NCT04258033) | Beijing Pearl Biotechnology Limited Liability Company | 2020-01-17 |
| A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). (NCT06105619) | Beijing Pearl Biotechnology Limited Liability Company | 2018-10-08 |
Track Beijing Pearl Biotechnology Limited Liability Company automatically
Every clearance here is in the API, with alerts when new ones post.